[go: up one dir, main page]

NO2773633T3 - - Google Patents

Info

Publication number
NO2773633T3
NO2773633T3 NO12777930A NO12777930A NO2773633T3 NO 2773633 T3 NO2773633 T3 NO 2773633T3 NO 12777930 A NO12777930 A NO 12777930A NO 12777930 A NO12777930 A NO 12777930A NO 2773633 T3 NO2773633 T3 NO 2773633T3
Authority
NO
Norway
Application number
NO12777930A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2773633T3 publication Critical patent/NO2773633T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
NO12777930A 2011-11-02 2012-10-29 NO2773633T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02
EP12777930.4A EP2773633B1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
NO2773633T3 true NO2773633T3 (pl) 2017-12-30

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12777930A NO2773633T3 (pl) 2011-11-02 2012-10-29

Country Status (34)

Country Link
US (4) US8759349B2 (pl)
EP (1) EP2773633B1 (pl)
JP (1) JP6091513B2 (pl)
KR (1) KR102006612B1 (pl)
CN (2) CN106279110B (pl)
AP (1) AP2014007670A0 (pl)
AU (1) AU2012331274B2 (pl)
BR (1) BR112014010583A2 (pl)
CA (1) CA2854217C (pl)
CL (1) CL2014001047A1 (pl)
CO (1) CO6940429A2 (pl)
CY (1) CY1120974T1 (pl)
DK (1) DK2773633T3 (pl)
EA (1) EA025158B9 (pl)
EC (1) ECSP14001929A (pl)
ES (1) ES2645744T3 (pl)
GE (1) GEP20186880B (pl)
HR (1) HRP20171614T1 (pl)
HU (1) HUE034929T2 (pl)
IL (1) IL232035A (pl)
LT (1) LT2773633T (pl)
ME (1) ME02905B (pl)
MX (1) MX348522B (pl)
NO (1) NO2773633T3 (pl)
PE (1) PE20141607A1 (pl)
PH (1) PH12014500970B1 (pl)
PL (1) PL2773633T3 (pl)
PT (1) PT2773633T (pl)
RS (1) RS56498B1 (pl)
SG (1) SG11201401907TA (pl)
SI (1) SI2773633T1 (pl)
TN (1) TN2014000180A1 (pl)
UA (1) UA115868C2 (pl)
WO (1) WO2013064450A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR102006612B1 (ko) * 2011-11-02 2019-08-02 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법
AU2014284268A1 (en) 2013-07-02 2016-01-07 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) * 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
KR20170076673A (ko) * 2014-10-24 2017-07-04 오노 야꾸힝 고교 가부시키가이샤 Kcnq2∼5 채널 활성화제
HK1246718A1 (zh) * 2015-01-07 2018-09-14 斯克利普斯研究所 用於治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (pl) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
JP2004513870A (ja) 1999-07-19 2004-05-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ナトリウムチャネルブロッカーの結合物及びその使用法
WO2001052902A1 (en) 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
EP1786427A4 (en) 2004-08-18 2009-11-11 Michael R Johnson BLOCKERS OF SODIUM CHANNELS OF PYRAZINOYLGUANIDINE WITH AMIDE AND ALIPHATIC ESTER
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008013557A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
ES2361595T3 (es) * 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
CN102015662A (zh) * 2008-05-13 2011-04-13 诺瓦提斯公司 3,5-二氨基-6-氯-吡嗪-2-甲酸衍生物和它们作为上皮钠通道阻断剂用于治疗气道疾病的用途
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013064451A1 (en) 2011-11-02 2013-05-10 Boehringer Ingelheim International Gmbh Novel process for the preparation of acylguanidines and acylthioureas
KR102006612B1 (ko) * 2011-11-02 2019-08-02 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법

Also Published As

Publication number Publication date
TN2014000180A1 (en) 2015-09-30
HUE034929T2 (en) 2018-03-28
MX2014005166A (es) 2014-05-28
AU2012331274B2 (en) 2017-06-08
SI2773633T1 (sl) 2017-11-30
US8759349B2 (en) 2014-06-24
CO6940429A2 (es) 2014-05-09
HRP20171614T1 (hr) 2017-12-01
US9920035B2 (en) 2018-03-20
CA2854217A1 (en) 2013-05-10
GEP20186880B (en) 2018-07-25
EA025158B1 (ru) 2016-11-30
JP6091513B2 (ja) 2017-03-08
ES2645744T3 (es) 2017-12-07
EP2773633A1 (en) 2014-09-10
ECSP14001929A (es) 2015-11-30
SG11201401907TA (en) 2014-05-29
PE20141607A1 (es) 2014-11-23
CY1120974T1 (el) 2019-12-11
CL2014001047A1 (es) 2014-11-07
AP2014007670A0 (en) 2014-05-31
KR102006612B1 (ko) 2019-08-02
PT2773633T (pt) 2017-11-14
IL232035A (en) 2017-05-29
WO2013064450A1 (en) 2013-05-10
AU2012331274A1 (en) 2014-04-03
LT2773633T (lt) 2017-11-10
US20130109697A1 (en) 2013-05-02
EA025158B9 (ru) 2018-03-30
BR112014010583A2 (pt) 2020-04-22
MX348522B (es) 2017-06-16
EP2773633B1 (en) 2017-08-02
CN104024244B (zh) 2016-09-14
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
US20150336933A1 (en) 2015-11-26
CN106279110B (zh) 2019-12-10
KR20140085498A (ko) 2014-07-07
RS56498B1 (sr) 2018-01-31
ME02905B (me) 2018-10-20
CA2854217C (en) 2019-12-31
JP2014534222A (ja) 2014-12-18
CN106279110A (zh) 2017-01-04
US20180194747A1 (en) 2018-07-12
EA201400521A1 (ru) 2014-09-30
PH12014500970A1 (en) 2014-06-09
US20140228374A1 (en) 2014-08-14
IL232035A0 (en) 2014-05-28
HK1196819A1 (zh) 2014-12-24
PH12014500970B1 (en) 2017-10-06
CN104024244A (zh) 2014-09-03
UA115868C2 (uk) 2018-01-10
DK2773633T3 (da) 2017-11-13

Similar Documents

Publication Publication Date Title
BR112013031251A2 (pl)
BR112013027245A2 (pl)
BR112013023185A2 (pl)
BR112013026905A2 (pl)
BR112013017670A2 (pl)
BR112013027830A2 (pl)
AP3853A (pl)
BR112013027452A2 (pl)
BR112013028733A2 (pl)
BR112013027121A2 (pl)
AP2016009466A0 (pl)
BR112013031556A2 (pl)
BR112013026790A2 (pl)
BR112013032366A2 (pl)
BR112013032380A2 (pl)
BR112013032377A2 (pl)
BR112013027836A2 (pl)
BR112013018949A2 (pl)
BR112013026895A2 (pl)
BR112013027761A2 (pl)
BR112013032392A2 (pl)
BR112013017878A2 (pl)
BR112013027871A2 (pl)
BR112013032394A2 (pl)
BR112013030734A2 (pl)